Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
======================================================================================================================================================

* David Gandara
* Martin Reck
* Denis Moro-Sibilot
* Julien Mazieres
* Shirish Gadgeel
* Stefanie Morris
* Andres Cardona
* Diana Mendus
* Marcus Ballinger
* Achim Rittmeyer
* Solange Peters